肿瘤细胞HLA II类表达与低肿瘤相关巨噬细胞数量预测口咽癌临床结局
在142例口咽鳞状细胞癌(OPSCC)患者中开展多变量分析,评估HLA I/II、PD-L1、PD1、T细胞和巨噬细胞等免疫变量。发现肿瘤细胞HLA II类分子表达与CD68+CD163+肿瘤相关巨噬细胞(TAM)呈负相关,高HLA-DP/DQ/DR表达和低TAM数量与更长的疾病特异性生存和无病生存(DFS)相关,CD8+FoxP3+T细胞与更短DFS相关。作者认为这些新预后标志物可用于筛选可从免疫治疗获益的患者。
要点
- 肿瘤细胞HLA II类表达与CD68+CD163+TAM数量呈负相关。
- 高HLA-DP/DQ/DR表达和低TAM数量与更长疾病特异性生存和DFS相关。
- CD8+FoxP3+T细胞在多元分析中与更短DFS相关。
核心结论
- 作者识别出口咽癌新的预后标志物,可用于筛选可从免疫治疗获益的患者。
研究设计与样本
- 对142例口咽鳞状细胞癌(OPSCC)患者进行临床与免疫变量的综合多变量分析。
主要发现
- 肿瘤细胞HLA II类分子表达与CD68+CD163+肿瘤相关巨噬细胞(TAM)呈负相关。
关键数值与推荐
- 高HLA-DP/DQ/DR表达和低TAM数量与更长疾病特异性生存和DFS相关。
- CD8+FoxP3+T细胞在多元分析中与更短DFS相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is a highly immunogenic tumor and differences in tumor microenvironment might contribute to the improved survival of HPV-positive OPSCC patient. METHODS: A comprehensive multivariate analysis with clinical and immune variables (human leukocyte antigen [HLA] I/II, programmed death ligand 1 (PD-L1), programmed death receptor 1 (PD1), T cells, and macrophages) was performed in 142 OPSCC patients. RESULTS: We found an inverse correlation between the expression of HLA class II molecules on tumor cells and CD68+ CD163+ tumor-associated macrophages (TAMs). High HLA-DP/DQ/DR expression and low number of TAMs were associated with longer disease-specific survival and disease-free survival (DFS). Furthermore, a new population of CD8+ FoxP3+ T cells was correlated with shorter DFS in multivariate analysis. CONCLUSIONS: \We identified new prognostic markers for patients with oropharyngeal cancer, which can be used for selecting patients that can benefit from immunotherapy.
引用
- Cioni B, Jordanova ES, Hooijberg E, et al. HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer. Head Neck. 2018. PMID: 30549362. doi:10.1002/hed.25442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。